![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
August 31, 2026
This phase 3 clinical trial for patients with soft tissue sarcoma is comparing chemotherapy before surgery versus surgery alone
August 31, 2026
This phase 2 clinical trial is testing two variations of the triplet combination of azacitidine, venetoclax, and gilteritinib compared to standard therapy
August 31, 2026
Guidance for a zero embargo mandate from the National Institutes of Health that aims to accelerate free public access to research results
July 31, 2026
This trial is testing an immune-based treatment combination (teclistamab and pomalidomide) for patients with multiple myeloma that has come back early
July 31, 2026
This phase 2 study is evaluating ivonescimab, a novel therapy designed to target the PD-1 and VEGF pathways simultaneously
June 29, 2026
This study is using PET imaging to guide treatment for prostate cancer recurrence
May 28, 2026
ACHIEVE (EA5221) is the first lung cancer clinical trial for older patients with metastatic NSCLC, comparing immunotherapy (pembrolizumab) with and without chemotherapy
May 20, 2026
This phase 3 clinical trial is comparing aromatase inhibitors and ribociclib, with and without chemotherapy, to prevent recurrence
April 24, 2026
This phase 2 trial is evaluating pembrolizumab immunotherapy after surgery in patients with recurrent or second primary head and neck cancer with high-risk features
April 24, 2026
This phase 3 trial seeks to determine if there is any survival benefit from adding a fourth drug to induction therapy—and if so, in which patients
March 30, 2026
This phase 3 clinical trial is evaluating a less intensive treatment approach for adults aged 75+ with early-stage melanoma
February 27, 2026
This phase 2 trial is evaluating whether broccoli sprout extract (sulforaphane) will reduce the risk of melanoma returning